Leflunomide-induced pulmonary arterial hypertension in a young man with nephrotic syndrome: A case report

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Drug-induced pulmonary arterial hypertension (PAH) has been widely reported but PAH caused by leflunomide is very rare. Here we report the case of a young man with nephrotic syndrome treated with leflunomide for 5 years before being admitted to our hospital for dyspnea. After discontinuing leflunomide treatment for 4 months, both the dyspnea and pulmonary artery systolic pressure improved. Right heart catheterization showed in a significant decrease in pulmonary vascular resistance and pulmonary artery pressure 4 months later. Because persistent PAH can lead to right heart failure and even death, identifying and excluding the risk factors is critical; discontinuing leflunomide until a definite cause is identified is highly recommended.

Cite

CITATION STYLE

APA

Luo, X., Li, J., Chen, S., & Luo, J. (2022). Leflunomide-induced pulmonary arterial hypertension in a young man with nephrotic syndrome: A case report. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.992457

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free